

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: True Leaf Medicine International Ltd. (the "Issuer").

Trading Symbol: MJ

Number of Outstanding Listed Securities: 94,953,800 common shares (plus 10,208,824 common shares reserved for issuance in the form of 5,826,158 warrants and 4,382,666 options)

Date: February 7, 2018

Report on Business

- 1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.**

During the past month, the Issuer generally continued to market its pet products and to develop its pet product line.

On January 22, 2018, the Issuer closed its previously announced Regulation A offering with non-Canadian investors raising an aggregate total of C\$10,000,000. The offering consisted of 14,285,715 common shares of the Issuer with a purchase price of \$0.70 per share. The Regulation A offering was qualified by the U.S. Securities and Exchange Commission November 21, 2017.

The offering was closed in two parts. The first closing occurred January 4, 2018 and the second and final closing occurred January 22, 2018. Boustead Securities LLC, a FINRA registered broker dealer, was the lead underwriter outside of Canada. The issuer paid Boustead \$800,000 representing 8% of the gross proceeds of the aggregate offering amount. It also issued 857,103 warrants representing 6% of the aggregate number of the securities sold in the offering. Each warrant exercisable for one share of the issuer at \$1.05 per share up to November 21, 2020. The Issuer also paid Boustead an advisory fee of US\$25,000 and offering expenses.

On January 24, 2018, on the same terms as the Regulation A offering the Issuer closed a concurrent Canadian private placement offering consisting of 5,864,636 common shares raising an aggregate total of \$4,105,245.20. The Canadian offering was non-brokered and no commissions or fees were paid in connection with this offering. The Canadian offering is subject to a four month hold period.

In total the Issuer the issuer raised \$14,105,245.20 in the two offerings.

On January 19, 2018, the Issuer's wholly owned subsidiary True Leaf Medicine Inc. ("TLM") completed the purchase of a 40-acre parcel of land in Lumby, BC (the "Property") from a private British Columbia company. TLM paid an initial sum of \$100,000 on entering into the option agreement and paid an additional \$3,200,000 plus GST on closing. The seller is at arm's length to the Issuer (the "Optionor"). TLM previously leased a portion of the Property from the Optionor.

TLM expects to use the Property, as well as the existing building thereon, in connection with its proposed medical cannabis operations.

2. Provide a general overview and discussion of the activities of management.

Please see Item 1 above.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

None, except in the ordinary course of business.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

None.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

None.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

None.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

None.

8. Describe the acquisition of new customers or loss of customers.

None, except in the ordinary course of business.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

None.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

None, except in the ordinary course of business.

11. Report on any labour disputes and resolutions of those disputes if applicable.

None.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

None.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

Please see Item 1 above.

14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds ⁽¹⁾
Common Shares	8,833,590	These shares were issued on January 4, 2018 at a price of \$0.70 per share on first closing of Regulation A offering.	\$6,183,513 as set out in in Use of Proceeds in CSE Form 9 filed January 4, 2018.
Common Shares	36,300	These shares were issued on January 8, 2018 upon the exercise of outstanding warrants exercised at a price of \$0.45 per share.	\$16,335 for general corporate purposes.

Security	Number Issued	Details of Issuance	Use of Proceeds ⁽¹⁾
Common Shares	73,500	These shares were issued on January 8, 2018 upon the exercise of outstanding warrants exercised at a price of \$0.45 per share.	\$33,075 for general corporate purposes.
Common Shares	10,000	These shares were issued on January 8, 2018 upon the exercise of outstanding warrants exercised at a price of \$0.45 per share.	\$4,500 for general corporate purposes.
Common Shares	35,000	These shares were issued on January 8, 2018 upon the exercise of outstanding warrants exercised at a price of \$0.45 per share.	\$15,750 for general corporate purposes.
Common Shares	328,570	These shares were issued on January 8, 2018 upon the exercise of outstanding options exercised at a price of \$0.185 per share.	\$60,785 for general corporate purposes.
Common Shares	30,000	These shares were issued on January 12, 2018 upon the exercise of outstanding warrants exercised at a price of \$0.45 per share.	\$13,500 for general corporate purposes.
Common Shares	20,000	These shares were issued on January 12, 2018 upon the exercise of outstanding warrants exercised at a price of \$0.45 per share.	\$9,000 for general corporate purposes
Common Shares	30,000	These shares were issued on January 12, 2018 upon the exercise of outstanding warrants exercised at a price of \$0.45 per share.	\$13,500 for general corporate purposes.
Common Shares	100,000	These shares were issued on January 12, 2018 upon the exercise of outstanding warrants exercised at a price of \$0.45 per share.	\$45,000 for general corporate purposes.
Common Shares	100,000	These shares were issued on January 12, 2018 upon the exercise of outstanding warrants exercised at a price of \$0.45 per share.	\$45,000 for general corporate purposes.

Security	Number Issued	Details of Issuance	Use of Proceeds ⁽¹⁾
Common Shares	50,000	These shares were issued on January 12, 2018 upon the exercise of outstanding warrants exercised at a price of \$0.45 per share.	\$22,500 for general corporate purposes.
Common Shares	15,000	These shares were issued on January 12, 2018 upon the exercise of outstanding warrants exercised at a price of \$0.45 per share.	\$6,750 for general corporate purposes.
Common Shares	40,000	These shares were issued on January 12, 2018 warrants exercised at a price of \$0.45 per share.	\$18,000 for general corporate purposes.
Common Shares	24,000	These shares were issued on January 12, 2018 upon the exercise of outstanding warrants exercised at a price of \$0.45 per share.	\$10,800 for general corporate purposes.
Common Shares	63,700	These shares were issued on January 12, 2018 upon the exercise of outstanding warrants exercised at a price of \$0.45 per share.	\$28,665 for general corporate purposes.
Common Shares	40,000	These shares were issued on January 12, 2018 upon the exercise of outstanding warrants exercised at a price of \$0.45 per share.	\$18,000 for general corporate purposes.
Common Shares	31,660	These shares were issued on January 18, 2018 upon the exercise of outstanding warrants exercised at a price of \$0.45 per share.	\$14,247 for general corporate purposes.
Common Shares	80,000	These shares were issued on January 18, 2018 upon the exercise of outstanding warrants exercised at a price of \$0.45 per share.	\$36,000 for general corporate purposes.
Common Shares	10,000	These shares were issued on January 18, 2018 upon the exercise of outstanding warrants exercised at a price of \$0.45 per share.	\$4,500 for general corporate purposes.
Common Shares	50,000	These shares were issued on January 18, 2018 upon the	22,500 for general corporate purposes.

FORM 7 – MONTHLY PROGRESS REPORT

Security	Number Issued	Details of Issuance	Use of Proceeds ⁽¹⁾
		exercise of outstanding warrants exercised at a price of \$0.45 per share.	
Common Shares	200,000	These shares were issued on January 18, 2018 upon the exercise of outstanding warrants exercised at a price of \$0.45 per share.	90,000 for general corporate purposes.
Common Shares	228,571	These shares were issued on upon the exercise of outstanding warrants exercised at a price of \$0.15 per share.	34,285 for general corporate purposes.
Common Shares	200,000	These shares were issued on January 18, 2018 upon the exercise of outstanding warrants exercised at a price of \$0.45 per share.	90,000 for general corporate purposes.
Common Shares	33,333	These shares were issued on January 18, 2018 upon the exercise of outstanding warrants exercised at a price of \$0.45 per share.	15,000 for general corporate purposes.
Common Shares	30,000	These shares were issued on January 18, 2018 upon the exercise of outstanding warrants exercised at a price of \$0.45 per share.	13,500 for general corporate purposes.
Common Shares	20,000	These shares were issued on January 18, 2018 upon the exercise of outstanding warrants exercised at a price of \$0.45 per share.	9,000 for general corporate purposes.
Common Shares	5,452,125	These shares were issued on January 22, 2018 at a price of \$0.70 per share on final closing of Regulation A offering.	\$3,816,487.50 as set out in Use of Proceeds in CSE Form 9 filed January 22, 2018 and as amended January 31, 2018.
Common Shares	5,864,636	These shares were issued on January 24, 2018 at a price of \$0.70 per share on first closing of Canadian private placement offering.	\$4,105,245.20 as set out in Use of Proceeds in CSE Form 9 filed January 22, 2018 and as amended February 7, 2018.
Common Shares	15,000	These shares were issued on January 25, 2018 upon the	6,750 for general corporate purposes.

FORM 7 – MONTHLY PROGRESS REPORT

Security	Number Issued	Details of Issuance	Use of Proceeds ⁽¹⁾
		exercise of outstanding warrants exercised at a price of \$0.45 per share.	
Common Shares	100,000	These shares were issued on January 25, 2018 upon the exercise of outstanding warrants exercised at a price of \$0.45 per share.	45,000 for general corporate purposes.
Common Shares	25,000	These shares were issued on January 25, 2018 upon the exercise of outstanding warrants exercised at a price of \$0.45 per share.	11,250 for general corporate purposes.
Common Shares	100,000	These shares were issued on January 25, 2018 upon the exercise of outstanding option exercised at a price of \$0.395 per share.	39,500 for general corporate purposes.

(1) State aggregate proceeds and intended allocation of proceeds.

15. Provide details of any loans to or by Related Persons.

None. _____

16. Provide details of any changes in directors, officers or committee members.

None. _____

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

None. _____

[Certificate on Next Page]

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated February 7, 2018.

Darcy Bomford
Name of Director or Senior Officer

"Darcy Bomford"
Signature

Chief Executive Officer
Official Capacity

Issuer Details Name of Issuer	For Month End	Date of Report YY/MM/DD
True Leaf Medicine International Ltd.	January 2018	18/02/07
Issuer Address		
100 Kalamalka Lake Road, Unit 32		
City/Province/Postal Code	Issuer Fax No.	Issuer Telephone No.
Vernon, British Columbia V1T 9G1	N/A	778.475.5323
Contact Name	Contact Position	Contact Telephone No.
Darcy Bomford	President, CEO, and Director	778.475.5323
Contact Email Address	Web Site Address	
Darcy@trueleaf.com	www.trueleaf.com	